Desquinolinyl Lenvatinib CAS 796848-79-8 Pite > 99.0% (HPLC) Lenvatinib Mesylate Faktori Entèmedyè
Ruifu Chimik Pwovizyon pou Lenvatinib Mesylate Entèmedyè ak Pite segondè
Lenvatinib Mesylate CAS 857890-39-2
4-Chloro-7-Methoxyquinoline-6-Carboxamide CAS 417721-36-9
Desquinolinyl Lenvatinib;1-(2-Chloro-4-Hydroxyphenyl)-3-Cyclopropylurea CAS 796848-79-8
Methyl 7-Methoxy-4-Oxo-1,4-Dihydroquinoline-6-Carboxylate CAS 205448-65-3
Methyl 4-Amino-2-Methoxybenzoate CAS 27492-84-8
5-(Methoxymethylene)-2,2-Dimethyl-1,3-Dioxane-4,6-Dione CAS 15568-85-1
4-Amino-3-Chlorophenol CAS 17609-80-2
4-Amino-3-Chlorophenol Hydrochloride CAS 52671-64-4
Methyl 4-Chloro-7-Methoxyquinoline-6-Carboxylate CAS 205448-66-4
Non Chimik | 1-(2-Kloro-4-Idroksifenil) -3-Cyclopropylurea |
Sinonim | Desquinolinyl Lenvatinib;Lenvatinib enpurte 16;Lenvatinib Desquinolinyl enpurite;Lenvatinib enpurite LFS-A;Lenvatinib Mesylate Entèmedyè Ⅲ;N-(2-Kloro-4-Idroksifenil)-N'-Cyclopropyl-Ure |
Nimewo CAS | 796848-79-8 |
Nimewo CAT | RF-PI1972 |
Estati Stock | Nan Stock, Pwodiksyon Echèl Jiska Tòn |
Fòmil molekilè | C10H11ClN2O2 |
Pwa molekilè | 226.66 |
Pwen bouyi | 364.6±42.0℃ |
Dansite | 1.43±0.10 g/cm3 |
Mak | Ruifu Chimik |
Atik | Espesifikasyon |
Aparans | Off-Blann a wouj Brown Solid Powder |
Pite / Metòd analiz | >99.0% (HPLC) |
Imidite (KF) | <0.50% |
Rezid sou ignisyon | <0.20% |
Single enpurte | <0.50% |
Enpurte total | <1.00% |
Metal lou | <10ppm |
Enfrawouj Spectrum | Konfòm ak estrikti |
RMN | Konfòm ak estrikti |
Tès Creole | Enterprise Standard |
Itilizasyon | Entèmedyè nan Lenvatinib Mesylate (CAS: 857890-39-2) |
Pake: Boutèy, sak papye aliminyòm, 25kg / tanbou katon, oswa selon kondisyon kliyan an
Kondisyon Depo:Sere nan resipyan ki fèmen nan yon kote ki fre ak sèk;Pwoteje kont limyè ak imidite
1-(2-Chloro-4-Hydroxyphenyl)-3-Cyclopropylurea, konnen tou kòm Desquinolinyl Lenvatinib, (CAS: 796848-79-8) se yon entèmedyè oswa enpurte nan Lenvatinib Mesylate (CAS: 857890-39-2).Desquinolinyl Lenvatinib se yon metabolit Lenvatinib Mesylate ki se yon inibitè oral aktif nan plizyè reseptè tirozin kinaz ki gen ladan reseptè VEGF, FGF ak SCF.Lenvatinib se yon dwòg anti-kansè pou tretman sèten kalite kansè tiwoyid, ak potansyèlman pou lòt kansè tou.Nan dat 13 fevriye 2015, US FDA te apwouve Lenvatinib dwòg antikansè pou tretman kansè tiwoyid.Lenvatinib se yon inibitè anzim milti-sib, ki kapab anpeche VEGFR2 ak VEGFR3 (reseptè faktè kwasans endothelial vaskilè).Non komèsyal Lenvatinib se Lenvima.